← Browse by Condition
Medical Condition

neoplasm recurrence local

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for neoplasm recurrence local sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neoplasm recurrence local Clinical Trials

How many clinical trials are currently recruiting for neoplasm recurrence local?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for neoplasm recurrence local, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neoplasm recurrence local?
neoplasm recurrence local research spans Phase 1 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neoplasm recurrence local clinical trial?
Eligibility criteria for neoplasm recurrence local trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Top Sponsors
CHU de Quebec-Universite Laval 1 trial
University of Chicago 1 trial

Recruiting Clinical Trials

NCT07483658
Recruiting
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
Enrollment
434 pts
Location
Canada
Sponsor
CHU de Quebec-Universite Laval
View Trial →
NCT06912087 Phase 1
Recruiting
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Enrollment
36 pts
Location
United States
Sponsor
University of Chicago
View Trial →

Related Conditions

reccurent metastatic solid tumor disease (1) prostate cancer post prostatectomy (1) prostate cancer (1) prostatic neoplasms (1) biochemical recurrence of malignant neoplasm of prostate (1) head and neck neoplasms (1) carcinoma squamous cell (1) neoplasm metastasis (1) recurrent squamous cell carcinoma (1) metastatic squamous cell carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology